

Food and Drug Administration
Rockville MD 20857

APR 19 1994

Re: Zosyn®
Docket No. 94E-0071

Charles E. Van Horn
Patent Policy and Projects Administrator
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, D.C. 20231

RECEIVED
94 APR 22 AM 9:27
DEPUTY ASSISTANT
COMMISSIONER FOR PATENTS

Dear Mr. Van Horn:

This is in regard to the application for patent term extension for U.S. Patent No. 4,562,073 filed by Taiho Pharmaceutical Company Ltd., under 35 U.S.C. § 156. The human drug product claimed by the patent is Zosyn® (tazobactam sodium and piperacillin sodium), which was assigned New Drug Application (NDA) 50-684.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the active ingredient tazobactam sodium; products have been previously approved containing piperacillin sodium.

The NDA was approved on October 22, 1993, which makes the submission of the patent term extension application on December 20, 1993, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A), we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely,

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Robert B. Murray
Nikaido, Marmelstein, Murray & Oram
655 Fifteenth Street, N.W.
Suite 330
Washington, D.C. 20005-5701